O-011Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC). (20th June 2018) - Merle, P; Rimassa, L; Ryoo, B; Cicin, I; Harris, W; Banu, E; Sarker, D; Tan, B; Van Vlierberghe, H; Sen, S; Love, C; Cheng, A; et al.